Amgen's Imdelltra with Imfinzi cuts lung cancer death risk by 58% in trial

Amgen's Imdelltra combined with AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% compared with Imfinzi alone in extensive-stage small cell lung cancer, according to trial data. Patients on both drugs lived a median 21.1 months versus 12.7 months, and nearly 80% were alive after a year, compared with 53% on Imfinzi alone.